Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today – Inhibikase Therapeutics


Inhibikase Therapeutics Inc IKT shares are trading higher by 31.1% to $1.56 during Wednesday’s session after the company announced the pricing of an approximately $110 million private placement financing.

What Else: Inhibikase says the funds will support a Phase 2b trial for pulmonary arterial hypertension (PAH) and general corporate needs. Led by Soleus Capital and joined by investors such as Sands Capital and Blackstone, the deal involves the sale of common stock, pre-funded warrants and accompanying Series A-1 and B-1 warrants.

As part of the transaction, two board members will resign, and four new directors, including Roberto Bellini and Amit Munshi, will join. Bellini will become the independent chair. The placement is set to close on October 21, with Jefferies as the lead placement agent.

Read Also: Disney World Closes Early As Hurricane Milton Approaches Florida: Parks Brace For Impact

How To Buy IKT Stock

By now you’re likely curious about how to participate in the market for Inhibikase Therapeutics – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,’ which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

In the the case of Inhibikase Therapeutics, which is trading at $1.59 as of publishing time, $100 would buy you 62.89 shares of stock.

If you’re looking to bet against a company, the process is more complex. You’ll need access to an options trading platform, or a broker who will allow you to ‘go short’ a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, IKT has a 52-week high of $3.82 and a 52-week low of $0.79.

Market News and Data brought to you by Benzinga APIs



Read More: Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today – Inhibikase Therapeutics

category: NewsCMS: WordPressPageIsBzPro: BZsymbol: IKTtag: why it's moving
Comments (0)
Add Comment